Primary Angle-closure Glaucoma
Conditions
Interventions
1:Trabeculectomy-Medication-Second surgery (SMS) ste
2:laser peripheral iridotomy (LPI)-Medication-Surgery
Sponsors
Beijing Tongren Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients definitely diagnosed as chronic PACG: IOP>24mmHg; Peripheral anterior synechia of iris>=120 degree or >=4 o'clock; Definite glaucoma induced optical nerve damage (such as narrowed optic disc edge, edge incisure, nerve fiber layer defect) and the corresponding repeatable visual field defect (GHT shows three consecutive relative scotomas (p =0.32); 4. Aged between 40 and 70 years old; 5. Willing to cooperate and with tolerance to the ophthalmologic examination, laser or surgery treatment protocols; 6. Written informed consent obtained; 7. Patients with more than 4 years follow-up period by initial estimation.
Exclusion criteria
Exclusion criteria: 1. Secondary glaucoma (such as neovascular glaucoma , uveitis, external injury, lens expansion, etc. or acute angle-closure glaucoma (including patients with past history of acute onset or definite onset signs); 2. Severe visual field damage (MD>20dB) or non-glaucoma visual field damage (such as optic neuritis, papilledema, ischemic optico-neuropathy, cerebral disease, etc) and the reliable visual field examination result can not be obtained; 3. Patient with short axial length <20mm, patients with retinal vessel abnormality or retinal diseases which may effect the visual field examination result such advanced age related macular degeneration, arterial/venous obstruction, retinal detachment, active entophthalmia or uveitis; 4. Patients having received the conjunctiva and intraocular surgeries or with external injury effecting the visual pathway; Patients who may receive the surgery for cataract within 1 year; 5. Patients having taken the Pilocarpine for long time, and the pupil can not restore above 2.4mm three days after withdrawal; 6. Severe systemic diseases such as stroke, tumor as well as patients having taken the systemic anti-coagulants (such as Asprin) or anti-tumor drugs for long time; 7. Patients with single eye; 8. Patients who are unable or unwilling to accept the long term follow-up according to the project requirements; 9. Patients refusing to sign the informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression of visual field damage;Patient number needed to treat (NNT);cost-utility value;Incidence of complicatio; | — |
Secondary
| Measure | Time frame |
|---|---|
| life (visual) utility;intraocular pressure;visual acuity;visual function relatied quality of life questionar; | — |
Countries
China
Contacts
Public ContactNingli WANG
Outcome results
None listed